1	Hombre	hombre	NCMS000	C0025266#C0086418#C0043210	persona#organismo_vivo	0-6	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
2	de	de	SPS00	C0332285	atributo	7-9	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
3	52	52		-	-	10-12	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
4	años	año	NCMP000	C0439234	calificador	13-17	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
5	de	de	SPS00	C0001779_1	entidad_observable_1	18-20	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
6	edad	edad	NCFS000	C0001779_2	entidad_observable_2	21-25	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
7	derivado	derivar	VMP00SM	-	-	26-34	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
8	al	al	SP+DA	-	-	35-37	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
9	servicio	servicio	NCMS000	-	-	38-46	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
10	de	de	SPS00	C0332285	atributo	47-49	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
11	digestivo	digestivo	NCMS000	C0012237	sustancia	50-59	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
12	por	por	SPS00	C0678226	atributo	60-63	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
13	cuadro	cuadro	NCMS000	-	-	64-70	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
14	de	de	SPS00	C0332285	atributo	71-73	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
15	hematoquezia	hematoquezia	NC00SC0	C0018932	hallazgo	74-86	351_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-	-	-	-
16	,	,	Fc	-	-	86-87	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
17	tenesmo	tenesmo	NCMS000	C0232726	hallazgo	88-95	351_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-	-	-	-
18	y	y	CC	C1706368	calificador	96-97	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
19	reducción	reducción	NCFS000	C0333668	anomalía_morfológica	98-107	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
20	del	del	SP+DA	-	-	108-111	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
21	diámetro	diámetro	NCMS000	C1301886	calificador	112-120	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
22	de	de	SPS00	C0332285	atributo	121-123	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
23	las	el	DA0FP0	-	-	124-127	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
24	heces	hez	NCFP000	-	-	128-133	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
25	.	.	Fp	-	-	133-134	351_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-

1	Se	se	P00CN000	-	-	135-137	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
2	realizan	realizar	VMIP3P0	-	-	138-146	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
3	una	una		C0205447_1	calificador_1	147-150	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
4	serie	serie	NCFS000	C0205549	calificador	151-156	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
5	de	de	SPS00	C0332285	atributo	157-159	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
6	pruebas	prueba	NCFP000	-	-	160-167	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
7	,	,	Fc	-	-	167-168	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
8	diagnosticando	diagnosticar	VMG0000	-	-	169-183	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
9	se	se	PP3CN000	-	-	183-185	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
10	un	un		C0205447_1	calificador_1	186-188	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
11	adenocarcinoma	adenocarcinoma	NC00SC0	C0001418	anomalía_morfológica	189-203	351_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-	15	3230	Causada_por
12	de	de	SPS00	C0332285	atributo	204-206	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
13	sigma	sigma	NCMS000	-	-	207-212	351_QUEST_clinical_caseMIR	SENT2	B-Estructura_Corporal	-	11	3230	LOC
14	sin	sin	SPS00	C0332288	atributo	213-216	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
15	metastasis	metastasis	NCMN000	-	-	217-227	351_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	Negacion	-	-	-
16	a	a	SPS00	-	-	228-229	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
17	distancia	distancia	NCFS000	C0012751	calificador	230-239	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-
18	.	.	Fp	-	-	239-240	351_QUEST_clinical_caseMIR	SENT2	-	-	-	-	-

1	El	el	DA0MS0	-	-	241-243	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
2	paciente	paciente	NCCS000	C0030705	persona	244-252	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
3	es	ser	VSIP3S0	-	-	253-255	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
4	intervenido	intervenir	VMP00SM	-	-	256-267	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
5	quirúrgicamente	quirúrgicamente	RG	-	-	268-283	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
6	y	y	CC	C1706368	calificador	284-285	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
7	remitido	remitir	VMP00SM	C1691010_1	calificador_1	286-294	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
8	a	a	SPS00	C1691010_2	calificador_2	295-296	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
9	la	el	DA0FS0	-	-	297-299	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
10	consulta	consulta	NCFS000	C3543841#C0009818	metadato_fundacional#procedimiento	300-308	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
11	de	de	SPS00	C0332285	atributo	309-311	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
12	oncologia	oncologia	NCFS000	-	-	312-321	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
13	médica	médico	AQ0FS0	C0205476#C0031831	calificador#ocupación	322-328	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
14	para	para	SPS00	C0521125	calificador	329-333	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
15	valorar	valorar	VMN0000	-	-	334-341	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
16	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	342-353	351_QUEST_clinical_caseMIR	SENT3	B-Grp_Medicamento	-	-	-	-
17	quimioterapico	quimioterapico	AQ0MS00	-	-	354-368	351_QUEST_clinical_caseMIR	SENT3	I-Grp_Medicamento	-	16	73	MultiE
18	complementario	complementario	AQ0MS0	-	-	369-383	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-
19	.	.	Fp	-	-	383-384	351_QUEST_clinical_caseMIR	SENT3	-	-	-	-	-

1	¿	¿	Fia	-	-	385-386	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
2	Cual	cual	PI0CS000	-	-	386-390	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
3	de	de	SPS00	C0332285	atributo	391-393	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
4	los	el	DA0MP0	-	-	394-397	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
5	siguientes	siguiente	AQ0CP0	C0332282	atributo	398-408	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
6	factores	factor	NCMP000	-	-	409-417	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
7	es	ser	VSIP3S0	-	-	418-420	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
8	de	de	SPS00	C0332285	atributo	421-423	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
9	mal	mal	RG	C0278252_1	hallazgo_1	424-427	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
10	pronóstico	pronóstico	NCMS000	C0278252_2	hallazgo_2	428-438	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
11	tras	tras	SPS00	-	-	439-443	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
12	la	el	DA0FS0	-	-	444-446	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
13	resección	resección	NCFS000	C0728940_1	calificador_1	447-456	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
14	quirúrgica	quirúrgico	AQ0FS0	C0728940_2	calificador_2	457-467	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
15	y	y	CC	C1706368	calificador	468-469	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
16	habra	habra	NCFS000	-	-	470-475	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
17	que	que	CS	-	-	476-479	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
18	tener	tener	VMN0000	-	-	480-485	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
19	en	en	SPS00	C1720294#C0332285	calificador#atributo	486-488	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
20	cuenta	cuenta	NCFS000	-	-	489-495	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
21	a	a	SPS00	-	-	496-497	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
22	la	el	DA0FS0	-	-	498-500	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
23	hora	hora	NCFS000	C0040223#C0439227	calificador	501-505	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
24	de	de	SPS00	C0332285	atributo	506-508	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
25	planificar	planificar	VMN0000	-	-	509-519	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
26	el	el	DA0MS0	-	-	520-522	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
27	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	523-534	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
28	de	de	SPS00	C0332285	atributo	535-537	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
29	quimioterapia	quimioterapia	NCFS000	C0392920#C0013216#C3665472	régimen/tratamiento#procedimiento	538-551	351_QUEST_clinical_caseMIR	SENT4	B-Grp_Medicamento	-	-	-	-
30	?	?	Fit	-	-	551-552	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-
31	.	.	Fp	-	-	552-553	351_QUEST_clinical_caseMIR	SENT4	-	-	-	-	-

